RESOLUTIONS FROM EXTRAORDINARY GENERAL MEETING IN MOBERG DERMA AB (PUBL) HELD ON NOVEMBER 19, 2012

Approval of the acquisition of Alterna LLC and authorization for the Board of
Directors to execute a share issue in kind as part of the purchase consideration
in the acquisition of Alterna LLC
As previously announced, Moberg Derma (publ) has on 24 October, 2012 entered
into an agreement to acquire all shares in Alterna LLC (“Alterna”). Under the
agreement, the acquisition of Alterna was conditional upon approval by the
shareholders of Moberg Derma and authorization for the Board of Directors to
execute the share issue in kind. The extraordinary general meeting resolved to
approve the Board’s decision to acquire Alterna and to authorize the execution
of a share issue in kind of up to 825,652 shares as part of the purchase
consideration. The sellers have undertaken not to sell, transfer, pledge or
otherwise dispose of the shares in Moberg Derma for a period of twelve months
after completion of the acquisition.

Changes to the Board of Directors
The extraordinary general meeting resolved to increase the number of Board
Members to eight (8), with no deputies. George Aitken-Davies, partner and
founder of Altaris Capital Partners, was elected as new Board Member. It was
also decided that no directors’ fee shall be paid to George Aitken-Davies. The
Meeting's resolution regarding changes to the Board as set out above is
conditional and become effective upon closing of Moberg Derma’s acquisition of
the shares in Alterna.

Resolution on employee stock option plan 2012:2, directed issue of warrants for
the fulfillment of commitments in the employee stock option plan and approval of
the transfer of warrants to senior executives
In accordance with the Board’s proposal, the extraordinary general meeting
resolved to introduce stock option program 2012:2 directed to two senior
managers of Alterna who will assume management positions in the Group. The terms
of the program essentially corresponds to the conditions of existing incentive
programs for other employees of the company.

In order to secure the company’s commitments under the employee stock option
plan, the Meeting resolved on an issue of a maximum 126,813 warrants to the
company’s wholly-owned subsidiary Moberg Derma Incentives AB, whereof some of
the warrants are intended to hedge the costs (mainly social security
contributions or corresponding taxes) that may arise from the employee stock
option plan. In addition, the Meeting resolved to approve that the subsidiary is
entitled to transfer warrants or shares in the company to the participants in
the employee stock option plan, or otherwise dispose of the warrants, in order
to secure Moberg Derma’s commitments and costs in connection with the employee
stock option plan.

In the event that all warrants issued in respect of employee stock option plan
2012:2 are used to subscribe for new shares, the company’s share capital will
increase by SEK 12 681,30. This is equivalent to a dilution of approximately 1.2
per cent of the shares and votes in the company after the issue in kind as
described above.

Authorization of share issue
The Meeting resolved, in accordance with the proposal of the Board of Directors,
to authorize the Board of Directors to, within the scope of the articles of
association, with or without deviation from the shareholders’ preferential
right, on one or several occasions during the period until the next Annual
General Meeting, resolve to increase the company’s share capital by issuing new
shares in the company. The total number of shares issued in accordance with this
authorization may be equivalent to a maximum of ten per cent of the shares in
the company at the time of the extraordinary general meeting held on November
19, 2012.

About this information
Moberg Derma discloses this information pursuant to the Swedish Securities
Markets Act. The information was submitted for publication at 8.00 am (CET) on
November 20, 2012.
For additional information contact:
Peter Wolpert, CEO
Mobile: +46 (0)70 - 735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, head of investor relations
Mobile: +46 (0)73 – 355 26 01
Email: magnus.persson@mobergderma.se
About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical
pharmaceuticals for the treatment of common disorders through the use of
innovative drug delivery. The company’s products are based on proven compounds,
which reduce time to market, development costs and risk. Moberg Derma’s first
product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader
directly after launch in the autumn of 2010 and international launch is ongoing.
The portfolio ranges from approved and launched products to projects in the
preclinical and clinical phase. The shares of Moberg Derma are quoted on the
Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further
information, please visit: www.mobergderma.com